Welcome to Licensing Consulting Group

Licensing Consulting Group is at the forefront of the new economy and the global intellectual property marketplace. Our approach focuses on the business side of IP. We combine business acumen with IP knowledge to offer solutions focused on business goals and objectives. Our role varies from analysis and planning the IP strategy, to implementing and actively managing the licensing program, to training and leading the internal IP team.

About

Licensing Consulting Group specializes on the business development side of IP. Our services focus on one goal: capitalizing on your IP to generate revenue in as many ways as possible. Our role varies from IP strategy and planning, to executing and actively managing the licensing program.

UPCOMING EVENTS

LATEST NEWS

4 Reasons Why Big Med Device Companies Want to License Your Medtech IP

Big Med Device companies are facing a big problem – their buy to grow strategy isn’t working anymore. The can’t find enough small companies with new med tech in the market that aren’t extremely overpriced. Now big med device companies are looking at creating partnerships with earlier stage med device companies. Although it’s riskier, it’s the only way they can fill their big product pipelines. And that spells big licensing opportunities for startup and emerging med device companies.

Is Your Business Diving into the Costly “R&D Unknowns”?

Recently the University of Arizona licensed one of its latest technologies, a formulation for a new sunscreen, to a local company. The value of this new technology is the ingredients are combined in such a way that it keeps it from seeping into the skin. And that presented a great licensing opportunity for a small company who spotted the IP.

How to Prevent Your IP From Languishing in the Market

What happens when your licensing partner doesn’t meet their development milestones? You end the agreement. That’s just what happened with two very large pharmaceutical companies. These two global companies signed a licensing agreement worth over $300 million that included the development, marketing and sales of an antibody treatment. But the […]